ACYLHYDRAZONES FOR THE TREATMENT OF NEUROLOGICAL DISEASES

The invention relates to a group of compounds with a structural nucleus of acylhydrazone, which are capable of modulating the interaction between the proteins NCS-1 and Ric8a involved in the process of regulating the number of synapses and the probability of release of neurotransmitters. These compo...

Full description

Saved in:
Bibliographic Details
Main Authors PEREZ FERNANDEZ, RUTH, CANAL MARTIN, ANDREA, SANCHEZ BARRENA, MARIA JOSE, MANSILLA APARICIO, ALICIA
Format Patent
LanguageEnglish
French
Published 02.04.2020
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a group of compounds with a structural nucleus of acylhydrazone, which are capable of modulating the interaction between the proteins NCS-1 and Ric8a involved in the process of regulating the number of synapses and the probability of release of neurotransmitters. These compounds can therefore be used for the treatment of neurological diseases in which the number of synapses is affected, such as Alzheimer's disease, Huntington's disease or Parkinson's disease. La présente invention concerne un groupe de composés ayant un noyau structural en acylhydrazone qui présentent une capactié de modulation de l'interaction entre les protéines NCS-1 et Ric8a, impliquées dans le processus de régulation du nombre de synapses et la probabilité de libération de neurotransmetteurs. Ces composés, par conséquent, sont utiles pour le traitement de maladies neurologiques dans lesquelles le nombre de synapses est affecté, comme la maladie d'Alzheimer, la maladie de Huntington ou la maladie de Parkinson.
Bibliography:Application Number: CA20193114555